共 8 条
[1]
[2]
Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis[J] Nicole R Pinelli;Raymond Cha;Morton B Brown;Linda A Jaber Annals of Pharmacotherapy 2008,
[3]
Exenatide and pancreatitis: an update[J] Bain;Stephens Expert Opinion on Drug Safety 2008,
[4]
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized; double-blind; two-arm; parallel-group; placebo-controlled; 2-week study[J] Sherwyn L. Schwartz;Robert E. Ratner;Dennis D. Kim;Yongming Qu;Linda L. Fechner;Sheila M. Lenox;John H. Holcombe Clinical Therapeutics 2008,
[5]
Preparation and characterization of a novel exendin‐4 human serum albumin fusion protein expressed in Pichia pastoris[J] Yan‐ShanHuang;ZhiChen;Yi‐QiongChen;Guo‐ChangMA;Jian‐FengShan;WeiLiu;Lin‐FuZhou J. Peptide Sci. 2008,
[6]
Liraglutide; a once‐daily human GLP‐1 analogue; improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type?2 diabetes mellitus[J] Diabetic Medicine 2008,
[7]
Metabolic effects of two years of exenatide treatment on diabetes; obesity; and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label; uncontrolled extension of three double-blind; placebo-controlled trials[J] John B. Buse;David C. Klonoff;Loretta L. Nielsen;Xuesong Guan;Christopher L. Bowlus;John H. Holcombe;David G. Maggs;Matthew E. Wintle Clinical Therapeutics 2007,
[8]
Safety and Pharmacodynamics of CJC-1134-PC; a Novel GLP-1 Receptor Agonist; in Patients with Type 2 Diabetes Mellitus http://newsgroups.derkeiler.com/Archive/Alt/alt.support.diabetes/2007-0 7/msg02401.html ,